Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors.

Roy S, Weinstock JL, Ishino AS, Benites JF, Pop SR, Perez CD, Gumbs EA, Rosenbaum JA, Roccato MK, Shah H, Contino G, Hunter K.

J Clin Med Res. 2017 Jul;9(7):638-649. doi: 10.14740/jocmr3066w. Epub 2017 May 22.

2.

The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment.

Smith KB, Kang P, Sabbagh MN; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement (N Y). 2017 Jun;3(2):149-156. doi: 10.1016/j.trci.2017.01.001.

PMID:
28480324
3.

Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis.

Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J.

Alzheimers Dement (Amst). 2017 Feb 9;7:69-87. doi: 10.1016/j.dadm.2017.01.005. eCollection 2017. Review.

4.

Blood cholesterol in late-life and cognitive decline: a longitudinal study of the Chinese elderly.

Ma C, Yin Z, Zhu P, Luo J, Shi X, Gao X.

Mol Neurodegener. 2017 Mar 7;12(1):24. doi: 10.1186/s13024-017-0167-y.

5.

Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease.

Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ.

Alzheimers Res Ther. 2017 Feb 17;9(1):10. doi: 10.1186/s13195-017-0237-y.

6.

The Use of a Bayesian Hierarchy to Develop and Validate a Co-Morbidity Score to Predict Mortality for Linked Primary and Secondary Care Data from the NHS in England.

Crooks CJ, Card TR, West J.

PLoS One. 2016 Oct 27;11(10):e0165507. doi: 10.1371/journal.pone.0165507. eCollection 2016.

7.

Evolution of primary care databases in UK: a scientometric analysis of research output.

Vezyridis P, Timmons S.

BMJ Open. 2016 Oct 11;6(10):e012785. doi: 10.1136/bmjopen-2016-012785.

8.

Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel.

Page AT, Potter K, Clifford R, McLachlan AJ, Etherton-Beer C.

Intern Med J. 2016 Oct;46(10):1189-1197. doi: 10.1111/imj.13215.

9.

Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial.

Cooper SA, Ademola T, Caslake M, Douglas E, Evans J, Greenlaw N, Haig C, Hassiotis A, Jahoda A, McConnachie A, Morrison J, Ring H, Starr J, Stiles C, Sirisena C, Sullivan F.

Trials. 2016 Jul 29;17:370. doi: 10.1186/s13063-016-1370-9.

10.

Linking multiple pathogenic pathways in Alzheimer's disease.

Bou Khalil R, Khoury E, Koussa S.

World J Psychiatry. 2016 Jun 22;6(2):208-14. doi: 10.5498/wjp.v6.i2.208. eCollection 2016 Jun 22. Review.

11.

Simvastatin-induced cognitive dysfunction: two case reports.

Suraweera C, de Silva V, Hanwella R.

J Med Case Rep. 2016 Apr 5;10:83. doi: 10.1186/s13256-016-0877-8.

12.

Lipid Lowering Effects of Hydroalcoholic Extract of Anethum graveolens L. and Dill Tablet in High Cholesterol Fed Hamsters.

Abbasi Oshaghi E, Khodadadi I, Saidijam M, Yadegarazari R, Shabab N, Tavilani H, Goodarzi MT.

Cholesterol. 2015;2015:958560. doi: 10.1155/2015/958560. Epub 2015 Dec 28.

13.

Role of Liver X Receptor in AD Pathophysiology.

Sandoval-Hernández AG, Buitrago L, Moreno H, Cardona-Gómez GP, Arboleda G.

PLoS One. 2015 Dec 31;10(12):e0145467. doi: 10.1371/journal.pone.0145467. eCollection 2015.

14.

Statin Use, Incident Dementia and Alzheimer Disease in Elderly African Americans.

Hendrie HC, Hake A, Lane K, Purnell C, Unverzagt F, Smith-Gamble V, Murrell J, Ogunniyi A, Baiyewu O, Callahan C, Saykin A, Taylor S, Hall K, Gao S.

Ethn Dis. 2015 Aug 7;25(3):345-54. doi: 10.18865/ed.25.3.345.

15.

Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.

Leduc V, Théroux L, Dea D, Dufour R, Poirier J.

J Mol Neurosci. 2016 Jan;58(1):109-19. doi: 10.1007/s12031-015-0666-7. Epub 2015 Nov 5.

16.

The Association of Statin Use with Age-Related Macular Degeneration Progression: The Age-Related Eye Disease Study 2 Report Number 9.

Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Cukras C, Ferris FL 3rd, Chew EY; Age-Related Eye Disease Study 2 Research Group.

Ophthalmology. 2015 Dec;122(12):2490-6. doi: 10.1016/j.ophtha.2015.08.028. Epub 2015 Oct 4.

17.

LDL-lipids from patients with hypercholesterolaemia and Alzheimer's disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention.

Dias HK, Brown CL, Polidori MC, Lip GY, Griffiths HR.

Clin Sci (Lond). 2015 Dec;129(12):1195-206. doi: 10.1042/CS20150351. Epub 2015 Sep 23.

18.

Statins Reduces the Risk of Dementia in Patients with Late-Onset Depression: A Retrospective Cohort Study.

Yang YH, Teng HW, Lai YT, Li SY, Lin CC, Yang AC, Chan HL, Hsieh YH, Lin CF, Hsu FY, Liu CK, Liu WS.

PLoS One. 2015 Sep 18;10(9):e0137914. doi: 10.1371/journal.pone.0137914. eCollection 2015.

19.

Prescribing for Australians living with dementia: study protocol using the Delphi technique.

Page A, Potter K, Clifford R, McLachlan A, Etherton-Beer C.

BMJ Open. 2015 Aug 11;5(8):e008048. doi: 10.1136/bmjopen-2015-008048.

20.

Dose-specific effect of simvastatin on hypoxia-induced HIF-1α and BACE expression in Alzheimer's disease cybrid cells.

Jeong JH, Yum KS, Chang JY, Kim M, Ahn JY, Kim S, Lapchak PA, Han MK.

BMC Neurol. 2015 Jul 31;15:127. doi: 10.1186/s12883-015-0390-5.

Supplemental Content

Support Center